LAURUS LABS
|
LAURUS LABS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 6.64 | 2.93 | 14.56 | 15.40 | 18.33 |
| CEPS(Rs) | 14.55 | 10.26 | 20.81 | 20.17 | 22.16 |
| DPS(Rs) | 1.20 | 0.80 | 2.00 | 2.00 | 2.00 |
| Book NAV/Share(Rs) | 82.46 | 75.88 | 74.73 | 62.19 | 48.32 |
| Tax Rate(%) | 26.82 | 28.83 | 28.16 | 23.20 | 24.39 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 19.00 | 15.42 | 26.36 | 28.82 | 32.22 |
| EBIT Margin(%) | 12.61 | 8.32 | 21.09 | 24.03 | 28.45 |
| Pre Tax Margin(%) | 8.72 | 4.69 | 18.36 | 21.96 | 27.03 |
| PAT Margin (%) | 6.38 | 3.34 | 13.19 | 16.87 | 20.44 |
| Cash Profit Margin (%) | 14.13 | 10.97 | 18.55 | 21.96 | 24.70 |
| Performance Ratios | |||||
| ROA(%) | 4.00 | 2.10 | 10.89 | 13.09 | 20.87 |
| ROE(%) | 8.30 | 4.15 | 21.63 | 28.05 | 45.15 |
| ROCE(%) | 10.16 | 6.64 | 22.97 | 25.97 | 39.82 |
| Asset Turnover(x) | 0.63 | 0.63 | 0.83 | 0.78 | 1.02 |
| Sales/Fixed Asset(x) | 0.93 | 0.97 | 1.41 | 1.46 | 1.78 |
| Working Capital/Sales(x) | 7.01 | 6.98 | 5.87 | 7.44 | 7.79 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.07 | 1.04 | 0.71 | 0.69 | 0.56 |
| Receivable days | 120.60 | 117.42 | 88.66 | 98.37 | 79.52 |
| Inventory Days | 124.27 | 127.81 | 104.09 | 123.34 | 94.05 |
| Payable days | 153.14 | 135.42 | 106.10 | 175.76 | 155.37 |
| Valuation Parameters | |||||
| PER(x) | 92.37 | 133.90 | 20.12 | 38.31 | 19.75 |
| PCE(x) | 42.19 | 38.19 | 14.08 | 29.25 | 16.34 |
| Price/Book(x) | 7.44 | 5.16 | 3.92 | 9.49 | 7.49 |
| Yield(%) | 0.20 | 0.20 | 0.68 | 0.34 | 0.55 |
| EV/Net Sales(x) | 6.42 | 4.66 | 2.93 | 6.76 | 4.33 |
| EV/Core EBITDA(x) | 31.54 | 29.21 | 11.08 | 23.20 | 13.23 |
| EV/EBIT(x) | 50.90 | 56.00 | 13.90 | 28.12 | 15.21 |
| EV/CE(x) | 4.97 | 3.55 | 2.95 | 4.79 | 3.62 |
| M Cap / Sales | 5.96 | 4.19 | 2.61 | 6.42 | 4.04 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 10.18 | -16.55 | 22.39 | 2.54 | 69.99 |
| Core EBITDA Growth(%) | 40.62 | -49.70 | 11.16 | -8.68 | 175.97 |
| EBIT Growth(%) | 67.03 | -67.09 | 7.41 | -13.37 | 257.33 |
| PAT Growth(%) | 110.69 | -78.89 | -4.30 | -15.39 | 285.40 |
| EPS Growth(%) | 127.12 | -79.91 | -5.42 | -15.98 | -23.23 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.61 | 0.61 | 0.49 | 0.52 | 0.56 |
| Current Ratio(x) | 1.22 | 1.23 | 1.42 | 1.25 | 1.25 |
| Quick Ratio(x) | 0.68 | 0.64 | 0.73 | 0.59 | 0.61 |
| Interest Cover(x) | 3.24 | 2.29 | 7.71 | 11.59 | 20.09 |
| Total Debt/Mcap(x) | 0.08 | 0.12 | 0.12 | 0.05 | 0.07 |
Compare Financial Ratios of peers of LAURUS LABS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| LAURUS LABS | ₹44,371.3 Cr | 0.1% | 22.9% | 86.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹403,712.0 Cr | -1.2% | 1.3% | 5.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹176,623.0 Cr | -2% | 1.3% | 45.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹120,285.0 Cr | 1.4% | 11.9% | 15.7% | Stock Analytics | |
| CIPLA | ₹119,010.0 Cr | -0.6% | -2% | -1.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹104,118.0 Cr | -1.2% | -6.7% | -8.4% | Stock Analytics | |
LAURUS LABS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| LAURUS LABS | 0.1% |
22.9% |
86.3% |
| SENSEX | 0.1% |
1% |
2.6% |
You may also like the below Video Courses
